How it works, simply
It blocks PCSK9, helping the liver keep receptors that remove LDL from blood.
What the evidence tells us
Cholesterol reduction and prevention of clinical events are different outcomes; check what the exact label establishes.
Approved use: United States: Lipfendra as an adjunct to diet and exercise to reduce LDL cholesterol in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia.
Watch with PEP 7
A short introduction; the sources and limitations remain important.
Open video guide
Video guides are coming soon.
Risks and open questions
This brief guide does not summarize every contraindication or interaction. Use the current label for the exact product; the label directory is linked below.
Research and education only. PepGuide does not recommend medicines, doses or protocols.
Technical details and study context
Mechanism: Inhibits PCSK9 to increase LDL-receptor availability and lower LDL cholesterol.
Sponsor or developer: Merck
Studied or labeled topics: Hypercholesterolemia
2026-07-17: FDA announcement of the first approved oral PCSK9 inhibitor.
Commercial blend names and research vials do not inherit a medicine’s approval or manufacturing controls.
Sources and review dates
- FDA: Lipfendra approval announcement ↗ · Regulator · 2026-07-17
Readability updated October 10, 2026. Evidence review: September 23, 2026 (listed facts only). A wording update is not a new clinical review.